04:21 PM EDT, 03/19/2026 (MT Newswires) -- Relmada Therapeutics ( RLMD ) reported a Q4 loss late Thursday of $0.27 per diluted share, narrowing from a loss of $0.62 a year earlier.
Analysts polled by FactSet expected a loss of $0.15.
Cash reserves of $93 million as of Dec. 31, along with gross proceeds of $160 million from a PIPE financing, is expected to fund operations through 2029.